Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company has successfully activated clinical study sites for the Phase 2 study of BBT-401, a drug candidate for Ulcerative Colitis (UC) treatment.
The Phase 2 clinical study is a multi-center, randomized, double-blind, placebo-controlled study for evaluating the efficacy and safety of BBT-401 in groups of patients with active UC. The primary endpoint of the study will be the change from baseline in total Mayo Score at Week 8.
Three study sites located in California, Maryland and North Carolina have been activated and the patient participants enrollment is now underway. Bridge Biotherapeutics anticipates that seven study sites will be additionally initiated by early next year and dosing and clinical data analysis in the first out of three cohorts will be finalized by the second half year of 2019. The dose escalation of the second and the third cohorts will be determined based on the results of previous cohorts.
“We are very excited to initiate the Phase 2 study following the successful first-in-human study and Team Bridge will continue to commit to developing beneficial treatments for patients with UC and the site activation for the Phase 2 study is a crucial stepping stone for the goal,” stated Dr. Gwang-hee Lee, the Head of Translational Research at Bridge Biotherapeutics.
BBT-401, discovered by SKKU (Sungkyunkwan University) and KRICT (Korea Research Institute of Chemical Technology) is a GI-tract restricted small molecule inhibitor of Pellino-1. From the Phase I study, the drug candidate was proved to be well tolerated and safe in humans. Bridge Biotherapeutics and Daewoong Pharmaceutical Co., Ltd., a Korean pharmaceutical giant, have recently signed a license agreement for co-development of BBT-401 in Asian countries.
For More Information
1. Bridge Biotherapeutics, Inc.
Bridge Biotherapeutics is a virtually-operated, venture-backed clinical stage biotech engaged in the development of novel therapeutics in the therapeutic areas of high unmet needs such as ulcerative colitis, fibrotic diseases and cancers. Following its first compound BBT-401, BBT-877, a potent and selective Autotaxin (ENPP) inhibitor is being developed potentially for the treatment of various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH). Bridge Biotherapeutics is a JLABS tenant company at JLABS@TMC, Houston, TX.
2. About Pellino Proteins
Pellino proteins are a family of E3 ubiquitin ligases which are highly conserved across species in mammal. Pellinos also serve as scaffold proteins that bind to proteins in inflammatory signaling pathways, including IRAK4, MyD88 (myeloid differentiation primary response gene 88) and to RIPK1 in various physio-pathological conditions.
SOURCE Bridge Biotherapeutics, Inc.